Expert consensus on physician-pharmacist collaborative management of stable chronic obstructive pulmonary disease

Abstract

Chronic obstructive pulmonary disease (COPD) is a common chronic airway disease. COPD patients need lifelong treatment, and long-term standardized inhalation medication is the core of stable COPD drug therapy. But, in the process of COPD stabilization management, the use accuracy rate of inhalation device is low and compliance is poor, and in addition, chronic diseases such as ischemic heart disease, heart failure, hypertension and diabetes are common in COPD patients, and these complications often involve multiple medications, which have potential drug risks associated with drug interactions that affect patient outcomes. Based on the experience of pharmacists involved in the management of other chronic diseases, experts from Respiratory Equipment Technical Committee of China Association of Medical Equipment, jointly with Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society and Guangdong Pharmaceutical Association, developed expert consensus on physician-pharmacist collaborative management of stable chronic obstructive pulmonary disease, aiming to improve patients' treatment compliance and satisfaction, reduce the acute attack rate, and ultimately improve the treatment level of COPD.